Personalis (NASDAQ:PSNL - Get Free Report) is scheduled to be posting its quarterly earnings results after the market closes on Wednesday, November 6th. Analysts expect Personalis to post earnings of ($0.33) per share for the quarter. Personalis has set its FY 2024 guidance at EPS and its Q3 2024 guidance at EPS.Individual that wish to listen to the company's earnings conference call can do so using this link.
Personalis (NASDAQ:PSNL - Get Free Report) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.24) earnings per share for the quarter, topping analysts' consensus estimates of ($0.34) by $0.10. Personalis had a negative return on equity of 56.87% and a negative net margin of 101.78%. The firm had revenue of $22.58 million for the quarter, compared to analyst estimates of $19.81 million. During the same quarter in the prior year, the company posted ($0.50) earnings per share. On average, analysts expect Personalis to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Personalis Stock Performance
Personalis stock traded up $0.06 during midday trading on Wednesday, reaching $5.19. The company's stock had a trading volume of 522,993 shares, compared to its average volume of 703,257. The firm has a market capitalization of $269.56 million, a PE ratio of -2.70 and a beta of 1.92. Personalis has a fifty-two week low of $0.89 and a fifty-two week high of $7.20. The stock's 50 day simple moving average is $5.25 and its 200 day simple moving average is $3.15.
Analyst Upgrades and Downgrades
A number of analysts recently commented on PSNL shares. Needham & Company LLC boosted their price objective on shares of Personalis from $5.50 to $7.25 and gave the stock a "buy" rating in a report on Friday, August 16th. HC Wainwright upped their price target on Personalis from $7.50 to $9.00 and gave the stock a "buy" rating in a report on Monday, August 19th. Finally, BTIG Research raised their price objective on Personalis from $5.50 to $7.00 and gave the company a "buy" rating in a research note on Friday, August 16th.
Check Out Our Latest Research Report on Personalis
Personalis Company Profile
(
Get Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Recommended Stories
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
